Evidence map›Paper›PMID 42649408›Full record

ArticleNature microbiology2026

A Zika virus vaccine with E protein fusion loop mutations protects via CD8

Kantinan Chuensirikulchai, Qin Hui Li, Hsueh-Han Lu, Julia Timis, Manuel Montano, Luke Eder, Pradip Bhandari, Dawid Zyla, Maximilian Bunz, Henry Madany and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Kantinan ChuensirikulchaiCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.ORCID http://orcid.org/0009-0002-1141-6485
Qin Hui LiCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
Hsueh-Han LuCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
Julia TimisCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
Manuel MontanoCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
Luke EderCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
Pradip BhandariDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Dawid ZylaCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-8471-469X
Maximilian BunzCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-6767-8698
Henry MadanyCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
Rubens Prince Dos Santos AlvesCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
Paolla Beatriz Almeida PintoCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
Erin MauleCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
Michael NguyenCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-4184-7078
Erica Ollmann SaphireCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-1206-7451
Lakshmanane PremkumarDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0002-1736-1350
Annie Elong NgonoCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA. aelong@lji.org.ORCID http://orcid.org/0000-0002-6741-3518
Sujan ShrestaCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA. sujan@lji.org.ORCID http://orcid.org/0000-0003-2906-8474

Funding

Project 5: mAb Development Flaviviruses and AlphavirusesU19AI181960 · NIAID · WASHINGTON UNIVERSITY · PI DIAMOND, MICHAEL S, KUHN, RICHARD J. · 2024 to 2024
$46.7M
Development of a Replicon RNA-based Vaccine against Dengue and ZikaR01AI163188 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI SHRESTA, SUJAN · 2021 to 2025
$3.6M
Maternal Antibody-Mediated Enhancement of Dengue PathogenesisR01AI153500 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI SHRESTA, SUJAN · 2021 to 2025
$3.1M
A novel strategy for vaccine-induced protection against maternal-to-fetal transmission of Zika virusR01AI180196 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI Sujan Shresta · 2024 to 2026
$2.6M
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID) R01AI153500Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID) R01AI163188Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID) R01AI180196Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID) U19AI181960NIAID NIH HHS R01 AI153500NIAID NIH HHS R01 AI163188NIAID NIH HHS R01 AI180196NIAID NIH HHS U19 AI181960
6 · The paper itself

Abstract

There are currently no effective vaccines against Zika virus (ZIKV). Candidate vaccines target the ZIKV envelope (E) protein, the major target of anti-ZIKV neutralizing antibodies (nAbs). Here we utilized DNA and RNA platforms to compare virus-like particle vaccines with premembrane (prM) and E expressed either in the wild-type form (Z-prM/E-WT) or with fusion loop (FL) mutations (Z-prM/E-FLM), which limit antibody-dependent enhancement of infection. Both vaccines induced effective protection against infection in C57BL/6 Ifnar1

Identifiers

PMID42649408

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.